ONCE HLDG Stock

ONC

GB00BYQ94H38

OTC Markets Traded

News in other languages: ONCE HLDG

20-05-28

Oncimmune Holdings plc : Signature d'un nouveau contrat avec ROCHE

More news

Managers and Directors: ONCE HLDG

Manager	Title	Age	Since
Martin Gouldstone CEO	Chief Executive Officer	59	2023-07-31
Martin Hudson DFI	Director of Finance/CFO	-	2023-09-03
Hans-Dieter Zucht CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
John Goold BRD	Director/Board Member	55	2023-01-12
Martin Gouldstone BRD	Director/Board Member	59	2023-07-31

More insiders

Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.

Employees

Sector

More about the company

25-10-16	Oncimmune Holdings plc Announces Termination of Martin John Gouldstone as Director, Effective April 8, 2025	CI
25-07-09	Oncimmune Holdings plc Announces Termination of Sally Christina Waterman as Director, Effective July 8, 2025	CI
25-07-08	Oncimmune Holdings plc Announces Termination of Alistair John Macdonald as Director, Effective July 1, 2025	CI
25-03-17	Oncimmune enters administration after failing to sell subsidiary	AN
25-03-17	Oncimmune Begins Insolvency Process After Failing to Secure Buyer	MT
25-03-17	Oncimmune Holdings To Be Placed Into Administration	RE
25-02-24	Oncimmune Plans Funding, Partnership Amid Share Price Drop	MT
25-02-24	Oncimmune Appoints Alvarez & Marsal To Outreach Potential Partners For Unit	RE
25-02-11	Oncimmune Holdings plc Auditor Raises 'Going Concern' Doubt	CI
25-02-10	Oncimmune forecasts 33% revenue growth in 2025 after doubling in 2024	AN
25-02-10	Oncimmune Holdings Expects Fy25 Revenue In Region Of £4 Mln	RE
25-02-10	Earnings Flash (ONC.L) Oncimmune Holdings Posts FY24 Revenue GBP2.7M	MT
25-02-10	Earnings Flash (ONC.L) Oncimmune Holdings Posts FY24 Loss GBX-4.72	MT

24-05-24	Oncimmune Reports Robust Interim Results, Exceeding Previous Year's Revenue in Just Six Months	AQ
24-03-08	Oncimmune's strategic pivot aims for robust growth in 2024	AQ
23-12-05	Oncimmune "relaunch" already delivering results	AQ
23-05-05	Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights	AQ
23-04-12	Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/11/24	Martin Gouldstone	Free	Chief Executive Officer	589,971	0.7362%
11/11/24	Alistair Macdonald	Buy	Chairman	100,000	0.1248%
11/11/24	Martin Gouldstone	Buy	Chief Executive Officer	66,667	0.0832%

ONCE HLDG Stock

Stocks

ONC

GB00BYQ94H38

Latest news : ONCE HLDG

Press Releases: ONCE HLDG

News in other languages: ONCE HLDG

Managers and Directors: ONCE HLDG

Latest insider transactions

Company Profile